Tirzepatide is a dual GLP-1 and GIP receptor agonist peptide used to support glycemic control and weight management in research settings. It is typically administered via subcutaneous injection once weekly, with doses gradually increasing over several weeks to minimize potential side effects.
- Dual GLP-1 and GIP receptor agonist.
- Administered once weekly via subcutaneous injection.
- Typical dose increases every 4 weeks to reduce side effects.
- Designed for glycemic control and weight reduction.
- Reconstituted solution is stable for 28 days when refrigerated.
Reconstitution
Vial strength
40 mg
Bacteriostatic water
3 mL
Concentration
13.33 mg/mL
1 unit = 0.01 mL = 133.3 mcg (U-100 syringe)
- 1Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2Slowly inject the water down the wall of the Tirzepatide vial, avoiding foaming.
- 3Gently swirl or roll the vial until the peptide is fully dissolved; do not shake vigorously.
- 4Label the vial with the reconstitution date and store it in the refrigerator at 2-8 °C (35.6-46.4 °F), away from light.
- 5Ensure to use the reconstituted solution within 28 days.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 18.8 units (0.19 mL) |
| Weeks 5–8 | 5 mg | 37.5 units (0.38 mL) |
| Weeks 9–12 | 7.5 mg | 56.3 units (0.56 mL) |
| Weeks 13–16 | 10 mg | 75 units (0.75 mL) |
Protocol detail
| Start | Begin with 2.5 mg once weekly for the initial 4 weeks. |
|---|---|
| Escalate | Increase the dose by 2.5 mg every 4 weeks if tolerated. |
| Maintenance | Adjust to a weekly dose of 5–15 mg based on individual response and tolerability. |
| Frequency | Administer once per week via subcutaneous injection, targeting the same day each week. |
Overview at a glance
| Goal | Support glycemic control, weight management, and metabolic health through dual incretin receptor activation. |
|---|---|
| Schedule | Weekly subcutaneous injection on the same day each week for 12–16 weeks or more. |
| Dose Range | 2.5–15 mg weekly with 4-week dose increases. |
| Reconstitution | 3.0 mL bacteriostatic water per 40 mg vial yields 13.33 mg/mL concentration, allowing all doses to fit in a single syringe. |
| Storage | Frozen as lyophilized powder; refrigerated for up to 28 days after reconstitution. |
How it works
Tirzepatide is a unique dual agonist influencing both GLP-1 and GIP receptors. This combined action boosts insulin secretion in a glucose-dependent manner, reduces glucagon release, slows stomach emptying, and promotes feelings of fullness through appetite regulation in the brain. The synergistic effect of GIP activity, alongside GLP-1, amplifies its metabolic benefits, leading to more significant weight loss than GLP-1 agonists alone. With a half-life of approximately 5 days, it conveniently allows for a once-weekly dosing schedule.
Reported effects
- Significant reduction in HbA1c for individuals with type 2 diabetes.
- Substantial body weight reduction.
- Improvements in cardiovascular markers like lipid profiles and blood pressure.
Reported side effects
- Gastrointestinal issues (e.g., nausea, diarrhea, vomiting, constipation) — usually mild, temporary, and dose-dependent.
- Mild injection-site reactions (e.g., redness, irritation).
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F), protected from light. Do not freeze reconstituted solution. Use within 28 days.
Supplies
| Peptide vials | 1-4 vials of Tirzepatide (40 mg each), depending on treatment duration. |
|---|---|
| Insulin Syringes (U-100, 1 mL) | Plan for 8-16 syringes, one per weekly injection. |
| Bacteriostatic Water | 1-2 bottles (10 mL each) to reconstitute vials at 3.0 mL per vial. |
| Alcohol Swabs | At least 100-count box for cleaning vial stoppers and injection sites. |
| Sharps Container | For safe disposal of used needles and syringes. |
Important notes
- Always use new, sterile insulin syringes and dispose of them in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to prevent skin irritation.
- All doses up to 10 mg/week can be administered using a single 1 mL insulin syringe at the specified concentration.
- Inject slowly and pause a few seconds before withdrawing the needle.
- Keep a record of weekly doses, dates, and injection sites for consistency.
Frequently asked questions
What is the primary benefit of Tirzepatide’s dual agonist action?
The dual agonism of GLP-1 and GIP receptors in Tirzepatide leads to enhanced glucose control and more pronounced weight reduction compared to treatments that target only GLP-1.
How can I minimize gastrointestinal side effects when starting Tirzepatide?
To mitigate gastrointestinal side effects like nausea or diarrhea, Tirzepatide protocols involve a gradual increase in dosage every four weeks, allowing the body to adjust.
Is it important to inject Tirzepatide at the same time each week?
While you can inject at any time of day, consistency is key. Administering your weekly dose on the same day each week helps maintain stable peptide levels in your system.
What should I do if my reconstituted Tirzepatide solution shows signs of cloudiness or particles?
A properly reconstituted Tirzepatide solution should be clear. If you observe cloudiness, discoloration, or any particulate matter, do not use it, as this may indicate contamination or degradation.
Educational reference only. These figures summarise how Tirzepatide is commonly described in research literature and supplier documentation, including the Tirzepatide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Tirzepatide (10 mg Vial)
Dual incretin agonist for glycemic control and weight management.
Tirzepatide (15 mg Vial)
Dual agonist for glucose control and weight management.
Tirzepatide (20 mg Vial)
Dual agonist for glucose control and weight management.
Tirzepatide (30 mg Vial)
Dual GLP-1/GIP agonist for glycemic control and weight management.